DKSH and Lupin have entered into an exclusive license and supply agreement to commercialize five of Alvotech’s high-quality biosimilars in the Philippines.
The Philippines, August 25, 2022 – DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, and global pharma major Lupin Limited (Lupin) announced an exclusive license and supply agreement to commercialize five of Alvotech’s proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia® (denosumab 60mg/ml), Xgeva® (denosumab 70 mg/ml), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
According to the agreement, Lupin’s subsidiary in the Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for the distribution and commercialization of the biosimilars once approved.
These reference products are used to treat disorders relating to bone disease, oncology, immunology, and ophthalmology. This agreement enhances Multicare’s oncology, rheumatology, gastroenterology, and ophthalmology portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.
“We are pleased to announce the addition of five new biosimilar candidates to our portfolio, which will provide patients in the Philippines with effective, high-quality, and affordable treatment options,” said Gabriel Georgy, Regional Head Southeast Asia, Lupin.
Peter Dolinsky, Vice President, Own Brands, Asia Pacific at DKSH, added: “We are delighted to partner with Lupin and bring these important therapeutic offerings to patients in the Philippines. This partnership is in line with our purpose of enriching people’s lives, and we are proud to be working with a strong local partner to make this happen.”